The University of Colorado Denver | Anschutz Medical Campus is responsible for ensuring that activities involving recombinant DNA or select agents and other biological hazards at the university are in compliance with established National Institutes of Health (NIH) Guidelines for research involving recombinant DNA molecules and all other applicable federal, state and local requirements. This authority is placed with the Institutional Biosafety Committee and Department of Environmental Health & Safety Biosafety Program.
Research Involving Recombinant DNA
The IBC reviews and approves all proposals that anticipate use of DNA material. Please submit your IBC application via email. If you have any questions regarding research involving recombinant DNA, contact IBC@ucdenver.edu.
IBC Compliance Note: NIH Guidelines for Research Involving Recombinant DNA
The university requires that all use of recombinant DNA be registered with the Institutional Biosafety Committee. Many common uses of recombinant DNA, however, qualify for exemption under Section III-F of the NIH Guidelines. If your use of recombinant DNA qualifies for an exemption under these criteria, please fill out the IBC application. After review, the IBC will provide an exemption decision. If any changes are made to protocols for a study that has received an exemption from the IBC, an amendment must be submitted to the IBC.
If your use of recombinant DNA does not meet any of the exemption criteria above you must submit an application and undergo a full review by the IBC.
We have programs in place to assist with the management of: